Moreover, drug synergism studies proposed a combination of PI3Kα/δ and BCL2 blockade, using venetoclax, in BCR-dependent DLBCL cell lines [71], or even the use of a combination of PI3K and BTK inhibitors, to overcome ibrutinib resistance in ABC-DLCBL cell lines [72]. Here, BCL2 is linked to diffuse large B-cell lymphoma.